MedTrace Logo

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

NCT07240649 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-05

No results posted yet for this study

Summary

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.

Conditions

  • Post-COVID-19 Condition
  • Ulcerative Colitis
  • Crohn Disease
  • Calciphylaxis
  • Frostbite
  • Acute COVID-19
  • Pyoderma Gangrenosum
  • Pterygium
  • Hypospadias
  • Head Trauma
  • Pneumatosis Intestinalis
  • Ischemic Bowel
  • Raynaud Syndrome
  • Malignant Otitis Externa
  • Nonarteritic Anterior Ischemic Optic Neuropathy
  • Central Retinal Vein Occlusion
  • Femoral Head Necrosis
  • Invasive Fungal Infection
  • Chronic Anal Fissure
  • Vasculitic Ulcer
  • Graft-vs-Host Disease
  • Decubitus Ulcer
  • Greater Trochanteric Pain Syndrome
  • Rectovaginal Fistula
  • Pouchitis
  • Tinnitus
  • Clostridium Enterocolitis
  • Branch Retinal Artery Occlusion
  • Axonotmesis
  • Multiple Sclerosis
  • Inclusion Body Myositis
  • Epidermolysis Bullosa (EB)
  • Osteonecrosis
  • Ulcer Ischemic
  • Avascular Necrosis of Bone
  • Prosthesis Related Infections
  • Facial Filler Injections
  • Cystitis Chronic
  • Ligament Injury
  • Anastomosis, Leaking
  • Cartilage Injury

Interventions

DEVICE

Hyperbaric oxygen treatment (HBOT)

Hyperbaric oxygen refers to oxygen given at pressures higher than atmospheric pressure (higher than 1.4 ATA) in pressurized chamber.

DRUG

100% Oxygen

Receiving 100% oxygen as part of HBOT

Sponsors & Collaborators

  • Dartmouth College

    collaborator OTHER

  • Jay C. Buckey Jr.

    lead OTHER

Principal Investigators

  • Jay Buckey · Dartmouth-Hichcock Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2035-12-31
Completion
2035-12-31
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240649 on ClinicalTrials.gov